| Grant number: | 14/15286-0 |
| Support Opportunities: | Regular Research Grants |
| Start date: | March 01, 2015 |
| End date: | February 28, 2017 |
| Field of knowledge: | Biological Sciences - Immunology - Cellular Immunology |
| Principal Investigator: | Gil Benard |
| Grantee: | Gil Benard |
| Host Institution: | Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil |
| City of the host institution: | São Paulo |
| Associated researchers: | Maria Angela Bianconcini Trindade |
Abstract
Leprosy, caused by the bacillus Mycobacterium leprae, is a chronic transmissible disease with lesions of the skin, peripheral nerves and mucosa. The outcome of the infection and its clinical manifestations are driven by several factors, including the host immune response to the pathogen. The infection can progress to either the resistant pole (tuberculoid), to the susceptible pole (lepromatous pole), or to instable forms of the disease (borderline forms) which not infrequently is associated with reaction episodes. These episodes correspond to acute inflammatory exacerbations that may result in permanent neural damage and irreversible physical handicaps. Treatment of this condition is difficult and based on immunosuppressive drugs with many severe adverse effects (corticosteroids and talidomide). The hypothesis is that there is a loss of regulation of the immune response of the patients who develop reaction episodes, which would be due to deficiency in the number and/or function of T regulatory cells (Treg). These cells display potent mechanisms that are crucial for the regulation of the immune responses and its suppressor function is mediated either through molecules such as CTLA-4 and CD39 or through cytokines such as IL-10 and TGF- ². However, it is not clear up to know the role played by these cells in the reaction episodes. The aim of the project is to determine by immunohistochemistry the frequency of Treg in situ (biopsies of lesions from patients with reaction), evaluate the frequency and function of Treg in the peripheral blood of these patients, as well as the potential for in vitro induction/expansion of these cells. A better understanding of the role of Treg in reaction episodes can potentially contribute to the improvement of their treatment by introducing novel immunotherapies. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |